{"id":830855,"date":"2025-03-27T16:35:31","date_gmt":"2025-03-27T20:35:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/clearside-biomedical-announces-fourth-quarter-and-full-year-2024-financial-results-and-provides-corporate-update\/"},"modified":"2025-03-27T16:35:31","modified_gmt":"2025-03-27T20:35:31","slug":"clearside-biomedical-announces-fourth-quarter-and-full-year-2024-financial-results-and-provides-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/clearside-biomedical-announces-fourth-quarter-and-full-year-2024-financial-results-and-provides-corporate-update\/","title":{"rendered":"Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update"},"content":{"rendered":"
\n

\n – Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD –<\/em>\n <\/p>\n

\n – Asia-Pacific Partner\u2019s New Drug Application for ARCATUS<\/em>
\n \u00ae<\/sup>
\n (XIPERE<\/em>
\n \u00ae<\/sup>
\n ) for Uveitic Macular Edema Accepted for Regulatory Review in China –<\/em>\n <\/p>\n

\n – Multiple Medical Meeting Presentations Highlight Potential Advantages and Key Differentiators of Suprachoroidal Drug Delivery Utilizing Clearside\u2019s SCS Microinjector<\/em>
\n
\n \u00ae<\/em>
\n <\/sup>
\n –<\/em>
\n \n <\/p>\n

\n – Management to Host Webcast and Conference Call Today at 4:30 P.M. ET –<\/em>\n <\/p>\n

ALPHARETTA, Ga., March 27, 2025 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc.<\/a>\u00a0(Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS\u00ae<\/sup>), today announced financial results for the fourth quarter and year ended December 31, 2024, and provided a corporate update.<\/p>\n

\u201cWe are redefining the delivery of therapeutics to the retina through the suprachoroidal space with the proven reliability and broad applicability of our innovative SCS Microinjector\u00ae<\/sup>,\u201d said George Lasezkay, PharmD, JD, President and Chief Executive Officer. \u201cOver the past six months, we announced positive Phase 2b data, conducted a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), designed the CLS-AX (axitinib injectable suspension) Phase 3 program to maximize commercial potential in wet AMD, and supported several of our SCS Microinjector partners as they advance their suprachoroidal drug candidates into Phase 3 clinical trials.\u201d<\/p>\n

\u201cClearside has developed a differentiated platform of early and later stage SCS assets, has entered into multiple validating SCS collaborations, and has the potential for pipeline expansion opportunities in geographic atrophy, diabetic retinopathy, and diabetic macular edema,\u201d concluded Dr. Lasezkay.<\/p>\n

\n Key Recent Highlights<\/strong>\n <\/p>\n